Bone Abstracts

Menopause is accompanied by a decrease in bone mineral density which can be caused by a reduction in bone volume and/or degree of bone matrix mineralization. Both of them are suggested to contribute to the increased fracture risk in postmenopausal individuals. In the present work, we aimed for information whether a drop in bone matrix mineralization is occurring in the perimenopausal stage of women. For this purpose, we measured the bone mineralization density distribution (BM...

Introduction: Administration of antibodies that neutralize sclerostin has been demonstrated to increase bone mass. We report the key findings of a Phase 2 study of the human sclerostin antibody, blosozumab (bmab).Methods: Study GSDB was a randomized, parallel-design, double-blind placebo-controlled study, designed to assess the dose–response relationship of bmab in postmenopausal women with low bone mineral density (BMD; lumbar spine (LS) T...